Voxelotor
Most patients with sickle cell disease not prescribed disease-modifying therapy
The underutilization of disease-modifying therapy by people with sickle cell disease is “persistent and alarming,” according to an analysis of real-world data.
ASH sickle cell disease research priorities address pain, organ dysfunction, drug development
American Society of Hematology has issued new sickle cell disease research priorities, highlighting seven key focus areas for maximum impact and benefit to patients.
‘Discouraging’ results show stroke incidence rising among people with sickle cell disease
Stroke rates among individuals with sickle cell disease have increased steadily over the last 25 years despite guidelines aimed at prevention, according to results of a retrospective study.
Patients with sickle cell disease using disease-modifying therapies more, but not enough
Nearly three-quarters of individuals with sickle cell disease are not using disease-modifying therapies in their treatment, according to a study published in JAMA Network Open.
Life expectancy for people with sickle cell disease increases by a decade
Life expectancy for individuals with sickle cell disease has increased by a decade since 2008, according to a study conducted by Epic Research.
People with sickle cell disease seldom receive newer pain medications
Fewer than 4% of eligible individuals with sickle cell disease received prescriptions for newer FDA-approved pain medications, according to study results published in Blood Advances.
FDA expands Oxbryta approval for sickle cell disease
FDA grants priority review to Oxbryta for sickle cell disease
The FDA granted priority review to voxelotor for the treatment of children aged 4 to 11 years with sickle cell disease.
‘Continuous long-term education’ needed amid advances in sickle cell disease treatment
Sickle cell disease is the most common genetic disorder, affecting approximately 100,000 people in the United States.